Table. Baseline Patient Characteristics of the Multi-institutional High-risk Cohort, the NCDB High-risk Cohort, and the SEER High-risk Cohort.
| Characteristic | Patients, No. (%) | ||
|---|---|---|---|
| Multi-institutional cohort (n = 5275) | SEER cohort (n = 23 989) | NCDB cohort (n = 88 909) | |
| Follow-up, median (IQR), y | 5.1 (3.1-7.9) | 2.7 (1.2-4.5) | 3.8 (2.5-5.7) |
| Age, median (IQR) | 66 (60-72) | 71 (65-77) | 67 (61-73) |
| Gleason grade group | |||
| 1 | 402 (8) | 1528 (6) | 6387 (7) |
| 2 | 460 (9) | 2253 (9) | 9389 (11) |
| 3 | 426 (8) | 2125 (9) | 7058 (8) |
| 4 | 2512 (48) | 10 298 (43) | 38 348 (43) |
| 5 | 1475 (28) | 7785 (32) | 27 727 (31) |
| Clinical T category | |||
| T1 | 2582 (49) | 12922 (54) | 52907 (60) |
| T2 | 1943 (37) | 8395 (35) | 24871 (28) |
| T3 | 684 (13) | 2401 (10) | 10543 (12) |
| T4 | 66 (1) | 271 (1) | 588 (1) |
| PSA, median (IQR), ng/mL | 10.5 (5.9-23.2) | 13.8 (7.4-27.4) | 10.9 (6.2-25.9) |
| Positive cores, median (IQR), % | 50 (33-83) | 50 (33-83) | 50 (30-80) |
| Primary therapy | |||
| Surgery | 2883 (55) | 0 (0) | 37017 (42) |
| EBRT | 1669 (32) | 14087 (59) | 34529 (39) |
| EBRT plus BT | 723 (14) | 2065 (9) | 3744 (4) |
| Unknown or other | 0 (0) | 7837 (33) | 13619 (15) |
| PSMA upstage risk, median (IQR) | |||
| Any non-localized (N+M) | 16.7 (8.5-31.8) | 18.2 (9.3-35.4) | 17.3 (8.5-32.1) |
| Regional nodal (N) | 15.0 (8.0-27.3) | 16.2 (8.6-30.6) | 15.4 (8.0-27.7) |
| Distant metastatic (M) | 5.1 (2.1-12.2) | 5.4 (2.1-13.0) | 4.7 (1.9-11.7) |
| PSMA nomogram risk group | |||
| Group 1, ≤14% upstage risk | 2231 (42) | 9285 (39) | 36 694 (41) |
| Group 2, 14.1%-27% upstage risk | 1384 (26) | 6087 (25) | 23 418 (26) |
| Group 3, 27.1%-41% upstage risk | 845 (16) | 3922 (16) | 14 153 (16) |
| Group 4, >41% upstage risk) | 815 (16) | 4695 (20) | 14 644 (16) |
Abbreviations: BT, brachytherapy; EBRT, external beam radiotherapy; NCDB, National Cancer Database; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; SEER, Surveillance, Epidemiology, and End Results.
SI conversion: To convert PSA to micrograms per liter, multiply by 1.0.